Advertisement


Ruth O’Regan, MD, and Ann H. Partridge, MD, on The NRG Oncology/NSABP B-42, IDEAL, and DATA Studies

2016 San Antonio Breast Cancer Symposium

Advertisement

Ruth O’Regan, MD, of the University of Wisconsin, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss study findings from a session Dr. O’Regan moderated on three major trials addressing anastrozole after tamoxifen in HR-positive early breast cancer, letrozole in HR-positive disease, and extended letrozole treatment after adjuvant endocrine therapy (Abstracts S1-03, S1-05, S1-08).



Related Videos

Breast Cancer

Lisa A. Carey, MD, and Maki Tanioka, MD, on HER2+ Breast Cancer: Results From the CALGB 40601 Alliance Trial

Lisa A. Carey, MD, and Maki Tanioka, MD, both of the University of North Carolina, discuss study findings on weekly paclitaxel and trastuzumab with or without lapatin...

Breast Cancer

S.P. Somashekhar, MBBS, MCh(Onco), on Watson for Oncology: A Validation Study for Breast Cancer

S.P. Somashekhar, MBBS, MCh(Onco), of the Manipal Comprehensive Cancer Centre, discusses a study to assess the performance of IBM's artificial intelligence platform in comparison to a...

Breast Cancer

Samuel Smith, PhD, on Tamoxifen Adherence: Results of the IBIS-1 Study

Samuel Smith, PhD, of Queen Mary University of London, discusses study findings on menopausal symptoms as predictors of long‐term adherence in an International breast cancer intervent...

Breast Cancer

Matthew P. Goetz, MD, on Advanced Breast Cancer: Expert Perspectives

Matthew P. Goetz, MD, of the Mayo Clinic, reviews progress made during the past year on treatment of advanced disease.

Breast Cancer

Lisa A. Carey, MD, and Ingrid A. Mayer, MD, on Triple-Negative Breast Cancer: Treatment Challenges

Lisa A. Carey, MD, of the University of North Carolina, and Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discuss the current studies on neoadjuvant sy...

Advertisement

Advertisement



;
Advertisement